ESMO 2023 BioNTech Data

BNT314/GEN10591 - Designed to Boost Antitumor Immune Response Through EpCAM-Dependent 4-1BB Agonistic Activity Mechanism of action T cell tumor cell DuoBody-EpCAMX4-1BB EpCAM 4-1BB Expansion of tumor-infiltrating lymphocytes in human TIL cultures NK cells CD8+ T cells CD4+ T cells Treg cells 106- 106 106 106. TCR/CD3 complex 105- 105. MHCI/II-peptide 104- 104. T-cell activation markers (e.g. 4-1BB, CD25) 103 103 104 Cytokines ● No antibody o DuoBody-EpCAM×4-1BB (0.2 μg/mL) 105. 104 103 DuoBody-EpCAM x4-1BB (1 µg/mL) • M T-cell proliferation By cross-linking EpCAM + tumor cells with activated 4-1BB+ T cells, BNT314/GEN1059 exhibits conditional 4-1 BB agonist activity, resulting in enhanced T-cell proliferation and effector functions, such as cytokine secretion and cytotoxic activity BNT314/GEN1059 is hypothesized to boost existing antitumor immune responses and may be further exploited in combination with other immunotherapy First preclinical disclosure at ESMO 2023: DuoBody-EpCAM×4-1BB mediates conditional T-cell co-stimulation and promotes antitumor activity in preclinical models. Fellermeier-Kopf et al. Presented at ESMO 2023. #1072P 1. BNT314 (GEN1059) is partnered with Genmab based on 50/50 sharing of costs and profits EpCAM epithelial cell adhesion molecule; TCR = T cell receptor; CD = cluster of differentiation; MHC major histocompatibility complex; NK cell = natural killer cell; Treg cell regulatory T cell. 4 BIONTECH

View entire presentation